On April 29th, 2021, TogetHER for Health presented this webinar featuring researchers from the Single-dose HPV Vaccine Evaluation Consortium, reviewing recently released evidence on the potential for single-dose HPV vaccination to inform global policy discussions and program guidance, as well as to raise awareness and understanding of its implications.
The session provided updates from clinical trials, observational studies, and modeling analyses on the efficacy, immunogenicity, effectiveness, and cost-effectiveness of single dose HPV vaccination. If demonstrated to be effective, single-dose HPV vaccination could facilitate new options for current national programs by simplifying delivery and lowering program costs, potentially accelerating introduction of HPV vaccines into national immunization schedules.
- Dr. Gina Ogilvie from the University of British Columbia's School of Population and Public Health
- Dr. Anne Schuind from PATH's Center for Vaccine Innovation and Access
- Dr. Jane J. Kim from the Harvard T.H. Chan School of Public Health
View the recording and access the presentations and additional resources below, Further questions and comments can be sent to us at [email protected].
Presentation from this webinar:
Presenter: The Single-Dose HPV Vaccine Evaluation Consortium
Title: Updates and Resources on Single-Dose HPV Vaccine
Learn more about the Single-Dose HPV Vaccine Evaluation Consortium
Sign up for HPVflash, a newsletter on HPV vaccination and cervical cancer screening and treatment.